Episode Details

Moderna’s new mRNA flu vaccine, mFLUSIVA, just got FDA approval — the first of its kind — offering seniors and high-risk adults a powerful new shield against flu season. Built on the same tech that revolutionized COVID vaccines, it showed 27% better protection in trials, though some experienced mild side effects. Despite past skepticism about mRNA’s ability to keep up with mutating viruses, doctors see this as a vital tool to prevent serious illness. With faster development potential and global regulatory reviews underway, this could be a game-changer for fall and winter health.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/e4562187fcec5fd1